奥布替尼治疗复发或难治性边缘区淋巴瘤:一项2期、多中心、开放标签研究
在中国开展的多中心单臂2期研究中,复发或难治性边缘区淋巴瘤患者接受奥布替尼150 mg每日一次口服。中位随访24.3个月,独立评审委员会评估的总缓解率为58.9%,12个月无进展生存率82.8%,常见治疗相关不良事件为贫血和血细胞减少。
要点
- 复发或难治性边缘区淋巴瘤患者接受奥布替尼150 mg每日一次,独立评审委员会评估总缓解率58.9%。
- 中位随访24.3个月,12个月无进展生存率82.8%,12个月总生存率91.0%。
- 30.6%患者发生≥3级治疗相关不良事件,16.2%发生严重治疗相关不良事件。
核心结论
- 奥布替尼在中国复发或难治性边缘区淋巴瘤患者中显示出高缓解率、持久疾病缓解且耐受性良好。
研究设计与样本
- 在中国开展的2期、多中心、单臂、开放标签研究,评估奥布替尼150 mg每日一次口服治疗复发或难治性边缘区淋巴瘤。
- 共入组111例患者,其中90例经中心病理复核确诊为边缘区淋巴瘤,主要亚型为黏膜相关淋巴组织结外边缘区淋巴瘤(46.7%)和结节型边缘区淋巴瘤(35.6%)。
- 多数患者为晚期疾病,IV期占75.6%。
- 主要终点为独立评审委员会基于Lugano 2014分类评估的总缓解率,其他疗效、安全性和药代动力学特征为次要结局指标。
主要发现
- 中位随访24.3个月,独立评审委员会评估的总缓解率为58.9%(95%CI 48.0-69.2),完全缓解率11.1%,部分缓解率47.8%。
- 独立评审委员会评估的中位缓解持续时间34.3个月,中位无进展生存期未达到,12个月无进展生存率82.8%(95%CI 72.6-89.5)。
- 12个月总生存率91.0%(95%CI 82.8-95.4)。
- 常见任意级别治疗相关不良事件包括贫血(27.9%)、中性粒细胞计数降低(23.4%)、白细胞计数降低(18.0%)、血小板计数降低(17.1%)、尿血(16.2%)、皮疹(14.4%)和上呼吸道感染(10.8%)。
- 34例患者(30.6%)发生≥3级治疗相关不良事件,18例(16.2%)发生严重治疗相关不良事件,最常见为肺炎(5.4%),7例(6.3%)因治疗相关不良事件停用奥布替尼。
关键数值与推荐
- 独立评审委员会评估的总缓解率58.9%(95%CI 48.0-69.2),完全缓解率11.1%,部分缓解率47.8%。
- 中位缓解持续时间34.3个月,中位无进展生存期未达到,12个月无进展生存率82.8%(95%CI 72.6-89.5)。
- 12个月总生存率91.0%(95%CI 82.8-95.4)。
- ≥3级治疗相关不良事件发生率30.6%,严重治疗相关不良事件发生率16.2%,因治疗相关不良事件停药率6.3%。
临床怎么用
- 奥布替尼150 mg每日一次口服可作为中国复发或难治性边缘区淋巴瘤患者的一种治疗选择,需关注贫血、血细胞减少和肺炎等不良事件。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Marginal zone lymphoma (MZL) is an indolent type of non-Hodgkin lymphoma that develops through pathological B cell receptor signaling. Orelabrutinib, a new-generation oral small molecule Bruton's tyrosine kinase inhibitor, was evaluated in relapsed/refractory (r/r) MZL patients. Previously treated r/r MZL patients received orelabrutinib 150 mg once daily in a phase 2, multicenter, single-arm study conducted in China. The primary endpoint was overall response rate (ORR) assessed by an Independent Review Committee (IRC) based on the Lugano 2014 classification. Other efficacy, safety, and pharmacokinetic profiles were evaluated as secondary outcome measures. A total of 111 patients were enrolled, of which 90 patients had MZL confirmed by central pathology review, who were mainly with extra-nodal MZL of mucosa-associated lymphoid tissue (MALT, 46.7%) and nodal MZL (35.6%). The majority had late-stage disease, with stage IV accounting for 75.6%. After a median follow-up duration of 24.3 months, the IRC-assessed ORR was 58.9% (95% confidence interval [CI], 48.0-69.2), with rates of complete response and partial response being 11.1% and 47.8%, respectively. The IRC-assessed median duration of response was 34.3 months, and the IRC-assessed median progression-free survival (PFS) was not reached with a 12-month PFS rate of 82.8% (95% CI, 72.6-89.5). The rate of overall survival at 12 months was 91.0% (95% CI, 82.8-95.4). Common all-grade treatment-related adverse events (TRAEs) included anemia (27.9%), neutrophil count decrease (23.4%), white blood cell count decrease (18.0%), platelet count decrease (17.1%), blood present in urine (16.2%), rash (14.4%), and upper respiratory tract infection (10.8%). Thirty-four patients (30.6%) experienced grade 3 or higher TRAEs. Serious TRAEs occurred in 18 patients (16.2%), of which pneumonia (5.4%) was the most common. Seven patients (6.3%) discontinued orelabrutinib due to TRAEs. Orelabrutinib demonstrated high response rates with durable disease remission and was well tolerated in Chinese patients with r/r MZL.
引用
- Deng L, Li Z, Zhang H, et al. Orelabrutinib for the treatment of relapsed or refractory marginal zone lymphoma: A phase 2, multicenter, open-label study. Am J Hematol. 2023. PMID: 37647123. doi:10.1002/ajh.27064
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。